<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232683</url>
  </required_header>
  <id_info>
    <org_study_id>FLA 19-073</org_study_id>
    <nct_id>NCT04232683</nct_id>
  </id_info>
  <brief_title>Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders</brief_title>
  <official_title>Preoperative Tamsulosin to Prevent Postoperative Urinary Retention in Females After Surgery For Pelvic Floor Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that patients receiving preoperative Tamsulosin will have decrease rates of
      postoperative urinary retention (POUR) after surgery in females for pelvic floor disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective randomized control trial. Patients undergoing pelvic surgery will
      randomized into two groups. The study group will receive one oral dose of .4mg of Tamsulosin
      preoperatively.The control group will receive one placebo pill preoperatively. Success or
      failure of initial voiding trial in postoperative period will be measured. Patients who fail
      the voiding trial will be discharged home with Foley catheter as is standard protocol at our
      institution.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tamsulosin Effect</measure>
    <time_frame>Up to 4 hours after surgery while patient is in post-anesthesia care unit.</time_frame>
    <description>Assess the effect of Tamsulosin in preventing POUR, defined by failure of initial voiding trial postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Narcotic Use</measure>
    <time_frame>Up to 4 hours after surgery while patient is in post-anesthesia care unit.</time_frame>
    <description>Amount of postoperative narcotic use will be tracked to assess if increased narcotic use has an effect on postoperative voiding trial (The amount of narctoic use will be measured in milligrams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Tamsulosin on postoperative blood pressure</measure>
    <time_frame>Up to 4 hours after surgery while patient is in post-anesthesia care unit</time_frame>
    <description>A side effect of Tamsulosin in hypotension, therefore, postoperative blood pressure will be evaluated to see if Tamsulosin had a significant impact on blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urinary Retention</condition>
  <arm_group>
    <arm_group_label>Preoperative Tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group will receive one oral dose .4mg of Tamsulosin prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive one oral dose of placebo pill prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin 0.4Mg Capsule</intervention_name>
    <description>Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased</description>
    <arm_group_label>Preoperative Tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo pill given preoperatively</description>
    <arm_group_label>Preoperative Placebo</arm_group_label>
    <other_name>Preoperative Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Patient undergoing surgery for prolapse with or without mid-urethral sling procedure.

        ii. Specific surgical procedures include all vaginal, laparoscopic and robotic
        reconstructive or obliterative surgeries including the use of mid-urethral slings

        Exclusion Criteria:

        i. Diagnosis of urinary retention preoperatively (post void residual &gt;150ml)

        ii. Malignancy

        iii. History of neurological disease

        iv. History of spinal cord injuries

        v. Allergy to Tamsulosin

        vi. Perioperative complications requiring prolonged postoperative bladder drainage

        vii. Incontinence procedures other than mid-urethral slings
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maral Malekzadeh</last_name>
    <phone>954-659-5559</phone>
    <email>malekzm2@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Hurtado</last_name>
    <phone>954-659-5559</phone>
    <email>hurtade@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maral Malekzadeh</last_name>
      <phone>954-659-5559</phone>
      <email>malekzm2@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Eric Hurtado</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Female Pelvic Floor Disorders</keyword>
  <keyword>Postoperative Urinary Retention</keyword>
  <keyword>Tamsulosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
    <mesh_term>Pelvic Floor Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

